The Pharmacy and Therapeutics (P&T) Committee
The P&T Committee provides recommendations for the Medicaid Preferred Drug List (PDL). The Committee is composed of Physicians & Pharmacists who meet at least quarterly to consider PDL implementation. These meetings are generally scheduled on the third Thursday of every month at 7:00 A.M. in the Cannon Health Building at 288 N. 1460 W. in Salt Lake City, UT. The P&T Committee reserves the right to adjust the meeting schedule as necessary. Notices for exact meeting times and locations will be published in the Legal Notices sections of the Salt Lake Newspapers at least 24 hours in advance.
Public Comments for the P&T Committee:
The meetings are open to the public. To receive public notice for this meeting by email please sign up on the Utah Public Notice website.
Manufacturers are requested to submit any additional materials they would like reviewed as part of the process to:
Gary M. Oderda, Pharm.D., M.P.H
Professor and Director
Pharmacotherapy Outcomes Research Center
University of Utah College of Pharmacy
421 Wakara Way Suite 208
Salt Lake City, UT 84108
All materials must be clearly labeled that they are submitted for consideration as part of the State of Utah Medicaid Preferred Drug List Program review process. Materials must be received at least 60 days before the scheduled review date. Materials most useful to support the evidence-based process include any new evidence (information from clinical trials or studies when possible) after the Oregon monograph was prepared, unpublished materials the company would like considered as part of the process, or any other materials not likely to be included in a literature search.
Persons who wish to address the P&T Committee may contact Lisa Hunt by phone at 801-538-6317 or by email at least 7 calendar days prior to the meeting. Comments from visitors, while welcome, may be limited due to time constraints
Listed below is a P&T Committee class review tentative schedule:
Listed below are meeting minutes, recordings, agendas, criteria review documents, and reports regarding the P&T Committee. Clinical evidence documents prepared for the P&T Committee meetings will be kept on this website for 6 months.
P&T Tentative Schedule
Date Topic Agents
2/20/2014 Short Acting Opioid Agents Codeine products, tramadol products, hydrocodone products, hydromorphone, Levorphanol, Meperidine, Tapentadol IR, Paregoric
3/20/2014
Antiemetics Droperidol, Hydroxyzine, Meclizine, Nabilone, Prochlorperazine, Promethazine, Trimethobenzamide, Metoclopramide (Prokinetic Agent)
Appetite Stimulants Dronabinol, Megestrol
4/17/2014
Annual Training N/A
Epipen Formulations Adrenaclick, Auvi-Q, EpiPen Jr, Epinephrine
5/22/2014
Antihistamines 1st Generation Agents Brompheniramine, Carbinoxamine, Chlorpheniramine, Clemastine, Cyclizine, Cyproheptadine, Dexchlorpheniramine, Dimenhydrinate,Diphenhydramine, Doxylamine, Hydroxyzine (including all combination agents)
Antihistamines 2nd Generation Agents Cetirizine, Desloratadine, Fexofenadine, Ketotifen, Levocetirizine, Loratadine
(including all combination agents)
6/19/2014
No Meeting N/A
Meeting recordings will be available online for 1 year. For historical meeting recordings please contact us at medicaidpharmacy@utah.gov.
Search the following files. Note that '*' and '?' wildcards are supported.
| Name | Type | Last Modified |
| Board Meeting Audio Recordings | Folder | February 26, 2014 |
| Criteria Review Documents | Folder | December 20, 2013 |
| Draft Future Agendas | Folder | February 26, 2014 |
| Minutes | Folder | January 30, 2014 |
| Non-Preferred_Drug_Auth.pdf | February 15, 2012 | |